glp 1 controversy FDA says that the GLP-1 shortage is over Controversy surrounding diabetes drug, Ozempic,
Description
How Payer Friction and Patient Drop-Off Undermine Obesity GLP-1 Uptake The GLP-1 market is experiencing unprecedented demand, yet despite its clinical promise for obesity, diabetes, and other conditions, patient behavior and friction throughout the treatment journey continue to erode its commercial potential

In collaboration with Novo Nordisk, Hims & Hers soon will offer access to the only FDA-approved GLP-1 weight loss pill, alongside injectable Wegovy in all dosages

In clinical practice, drug selection should therefore prioritize factors such as tolerability, safety profile, adherence, cost, and patient preference rather than expecting major differences in cardiovascular efficacy.

Designed for 3ml vials approximately 17 mm in diameter and 38 mm tall

Get a free estimate in seconds with WeightWatchers.